Citrine Global Corp. | 10-Q: FY2025 Q2 EBIT: USD -455 K

EBIT: As of FY2025 Q2, the actual value is USD -455 K.

Segment Revenue

• The company did not generate any revenues from product sales as of June 30, 2025.

Operational Metrics

• Net Loss: The net loss for the six months ended June 30, 2025, was $942,000, compared to $1,502,000 for the same period in 2024.
• Operating Loss: The operating loss for the six months ended June 30, 2025, was $455,000, compared to $667,000 for the same period in 2024.
• Research and Development Expenses: $63,000 for the six months ended June 30, 2025, compared to $0 for the same period in 2024.
• Marketing, General and Administrative Expenses: $392,000 for the six months ended June 30, 2025, compared to $667,000 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $116,000 for the six months ended June 30, 2025, compared to - $30,000 for the same period in 2024.
• Net Cash Provided by Financing Activities: $123,000 for the six months ended June 30, 2025, compared to $26,000 for the same period in 2024.

Unique Metrics

• Fair Value Measurement of IBOT Options and Impairment of Nanomedic Investment: The company recorded an impairment loss of $432,000 during the period.

Future Outlook and Strategy

• Core Business Focus: The company is shifting its strategic focus to the defense and unmanned systems (UMS) and drone solutions sectors, with plans to establish the SkyTech Innovation and Production Center in Yerucham, Israel. This center will serve as a national hub for innovation and manufacturing in the field of unmanned systems, tailored to the operational needs of the defense sector.
• Non-Core Business: While the company is now primarily focused on defense technologies, it retains ownership of wellness-related assets, including equity stakes in iBOT and MyPlant, and continues to assess how these assets can be leveraged in the future.